Goralczyk Armin D, Obed Aiman, Schnitzbauer Andreas, Doenecke Axel, Tsui Tung Yu, Scherer Marcus N, Ramadori Giuliano, Lorf Thomas
Department of General and Visceral Surgery, University Medical Center Göttingen, 37099 Göttingen, Germany.
J Transplant. 2009;2009:759581. doi: 10.1155/2009/759581. Epub 2010 Feb 3.
Adult living donor liver transplantations (ALDLTs) across the ABO blood group barrier have been reported in Asia, North Americas, and Europe, but not yet in Germany. Several strategies have been established to overcome the detrimental effects that are attached with such a disparity between donor and host, but no gold standard has yet emerged. Here, we present the first experiences with three ABO-incompatible adult living donor liver transplantations in Germany applying different immunosuppressive strategies. Four patient-donor couples were considered for ABO-incompatible ALDLT. In these patients, resident ABO blood group antibodies (isoagglutinins) were depleted by plasmapheresis or immunoadsorption and replenishment was inhibited by splenectomy and/or B-cell-targeted immunosuppression. Despite different treatments ALDLT could safely be performed in three patients and all patients had good initial graft function without signs for antibody-mediated rejection (AMR). Two patients had long-term graft survival with stable graft function. We thus propose the feasibility of ABO-incompatible ALDLT with these protocols and advocate further expansion of ABO incompatible ALDLT in multicenter trials to improve efficacy and safety.
亚洲、北美和欧洲均已报道过跨越ABO血型屏障的成人活体肝移植(ALDLT),但德国尚未有此类报道。人们已经制定了多种策略来克服供体与受体之间这种差异所带来的不利影响,但尚未出现金标准。在此,我们介绍德国首例采用不同免疫抑制策略的3例ABO血型不相容成人活体肝移植的经验。4对患者-供体夫妇被考虑进行ABO血型不相容的ALDLT。在这些患者中,通过血浆置换或免疫吸附清除了常驻ABO血型抗体(同种凝集素),并通过脾切除术和/或针对B细胞的免疫抑制来抑制抗体补充。尽管治疗方法不同,但3例患者均成功实施了ALDLT,所有患者术后初期移植肝功能良好,无抗体介导排斥反应(AMR)迹象。2例患者长期存活,移植肝功能稳定。因此,我们认为采用这些方案进行ABO血型不相容的ALDLT是可行的,并主张在多中心试验中进一步扩大ABO血型不相容ALDLT的应用,以提高疗效和安全性。